Daito Pharmaceutical ,Ltd. EBIT

The latest EBIT for 4577.T is $4.2B as of May 2026. That compares with $3.1B in the prior-year period — up 37.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Daito Pharmaceutical ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 4577.T's EBIT moved from $3.1B to $4.2B — a 37.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Daito Pharmaceutical ,Ltd.'s operating scale or balance-sheet position.

Against its sector companies, 4577.T currently prints $4.2B for EBIT, while the sector average sits near $2.6T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at Daito Pharmaceutical ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $4.2B for 4577.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 4577.T's EBIT ($4.2B), review year-over-year change from $3.1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.